206 related articles for article (PubMed ID: 23948550)
1. microRNAs are important players in head and neck carcinoma: a review.
Janiszewska J; Szaumkessel M; Szyfter K
Crit Rev Oncol Hematol; 2013 Dec; 88(3):716-28. PubMed ID: 23948550
[TBL] [Abstract][Full Text] [Related]
2. MiR-21 as prognostic biomarker in head and neck squamous cell carcinoma patients undergoing an organ preservation protocol.
Arantes LM; Laus AC; Melendez ME; de Carvalho AC; Sorroche BP; De Marchi PR; Evangelista AF; Scapulatempo-Neto C; de Souza Viana L; Carvalho AL
Oncotarget; 2017 Feb; 8(6):9911-9921. PubMed ID: 28039483
[TBL] [Abstract][Full Text] [Related]
3. Expression of TP53 mutation-associated microRNAs predicts clinical outcome in head and neck squamous cell carcinoma patients.
Ganci F; Sacconi A; Bossel Ben-Moshe N; Manciocco V; Sperduti I; Strigari L; Covello R; Benevolo M; Pescarmona E; Domany E; Muti P; Strano S; Spriano G; Fontemaggi G; Blandino G
Ann Oncol; 2013 Dec; 24(12):3082-8. PubMed ID: 24107801
[TBL] [Abstract][Full Text] [Related]
4. An Update on Cellular MicroRNA Expression in Human Papillomavirus-Associated Head and Neck Squamous Cell Carcinoma.
Emmett S; Whiteman DC; Panizza BJ; Antonsson A
Oncology; 2018; 95(4):193-201. PubMed ID: 29920485
[TBL] [Abstract][Full Text] [Related]
5. Role of miRNA in head and neck squamous cell carcinoma.
Masood Y; Kqueen CY; Rajadurai P
Expert Rev Anticancer Ther; 2015 Feb; 15(2):183-97. PubMed ID: 25367254
[TBL] [Abstract][Full Text] [Related]
6. Role of molecular markers and gene profiling in head and neck cancers.
Gold KA; Kim ES
Curr Opin Oncol; 2009 May; 21(3):206-11. PubMed ID: 19346943
[TBL] [Abstract][Full Text] [Related]
7. Integrative analysis of the microRNA-mRNA response to radiochemotherapy in primary head and neck squamous cell carcinoma cells.
Summerer I; Hess J; Pitea A; Unger K; Hieber L; Selmansberger M; Lauber K; Zitzelsberger H
BMC Genomics; 2015 Sep; 16(1):654. PubMed ID: 26328888
[TBL] [Abstract][Full Text] [Related]
8. MicroRNAs as Important Players and Biomarkers in Oral Carcinogenesis.
Min A; Zhu C; Peng S; Rajthala S; Costea DE; Sapkota D
Biomed Res Int; 2015; 2015():186904. PubMed ID: 26504785
[TBL] [Abstract][Full Text] [Related]
9. The microRNA signatures: aberrantly expressed microRNAs in head and neck squamous cell carcinoma.
Koshizuka K; Hanazawa T; Fukumoto I; Kikkawa N; Okamoto Y; Seki N
J Hum Genet; 2017 Jan; 62(1):3-13. PubMed ID: 27557665
[TBL] [Abstract][Full Text] [Related]
10. DNA methylation regulated microRNAs in HPV-16-induced head and neck squamous cell carcinoma (HNSCC).
Sannigrahi MK; Sharma R; Singh V; Panda NK; Rattan V; Khullar M
Mol Cell Biochem; 2018 Nov; 448(1-2):321-333. PubMed ID: 29455435
[TBL] [Abstract][Full Text] [Related]
11. Involvement of aberrantly expressed microRNAs in the pathogenesis of head and neck squamous cell carcinoma.
Koshizuka K; Hanazawa T; Arai T; Okato A; Kikkawa N; Seki N
Cancer Metastasis Rev; 2017 Sep; 36(3):525-545. PubMed ID: 28836104
[TBL] [Abstract][Full Text] [Related]
12. Antitumor miR-150-5p and miR-150-3p inhibit cancer cell aggressiveness by targeting SPOCK1 in head and neck squamous cell carcinoma.
Koshizuka K; Hanazawa T; Kikkawa N; Katada K; Okato A; Arai T; Idichi T; Osako Y; Okamoto Y; Seki N
Auris Nasus Larynx; 2018 Aug; 45(4):854-865. PubMed ID: 29233721
[TBL] [Abstract][Full Text] [Related]
13. Deep sequencing-based microRNA expression signatures in head and neck squamous cell carcinoma: dual strands of pre-miR-150 as antitumor miRNAs.
Koshizuka K; Nohata N; Hanazawa T; Kikkawa N; Arai T; Okato A; Fukumoto I; Katada K; Okamoto Y; Seki N
Oncotarget; 2017 May; 8(18):30288-30304. PubMed ID: 28415821
[TBL] [Abstract][Full Text] [Related]
14. Co-targeting of multiple microRNAs on factor-Inhibiting hypoxia-Inducible factor gene for the pathogenesis of head and neck carcinomas.
Kao SY; Tsai MM; Wu CH; Chen JJ; Tseng SH; Lin SC; Chang KW
Head Neck; 2016 Apr; 38(4):522-8. PubMed ID: 25351569
[TBL] [Abstract][Full Text] [Related]
15. Circulating microRNAs as prognostic therapy biomarkers in head and neck cancer patients.
Summerer I; Unger K; Braselmann H; Schuettrumpf L; Maihoefer C; Baumeister P; Kirchner T; Niyazi M; Sage E; Specht HM; Multhoff G; Moertl S; Belka C; Zitzelsberger H
Br J Cancer; 2015 Jun; 113(1):76-82. PubMed ID: 26057452
[TBL] [Abstract][Full Text] [Related]
16. Multiple microRNA signature panel as promising potential for diagnosis and prognosis of head and neck cancer.
Subha ST; Chin JW; Cheah YK; Mohtarrudin N; Saidi HI
Mol Biol Rep; 2022 Feb; 49(2):1501-1511. PubMed ID: 34837627
[TBL] [Abstract][Full Text] [Related]
17. Clinical implications of hypoxia biomarker expression in head and neck squamous cell carcinoma: a systematic review.
Swartz JE; Pothen AJ; Stegeman I; Willems SM; Grolman W
Cancer Med; 2015 Jul; 4(7):1101-16. PubMed ID: 25919147
[TBL] [Abstract][Full Text] [Related]
18. microRNAs deregulation in head and neck squamous cell carcinoma.
Carron J; Torricelli C; Silva JK; Queiroz GSR; Ortega MM; Lima CSP; Lourenço GJ
Head Neck; 2021 Feb; 43(2):645-667. PubMed ID: 33159410
[TBL] [Abstract][Full Text] [Related]
19. MicroRNAs as new biomarkers for human papilloma virus related head and neck cancers.
Wang Y; Wang J; Huang Y
Cancer Biomark; 2015; 15(3):213-8. PubMed ID: 25769448
[TBL] [Abstract][Full Text] [Related]
20. TRAF3/CYLD mutations identify a distinct subset of human papillomavirus-associated head and neck squamous cell carcinoma.
Hajek M; Sewell A; Kaech S; Burtness B; Yarbrough WG; Issaeva N
Cancer; 2017 May; 123(10):1778-1790. PubMed ID: 28295222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
